



## **EURONANOMED III**

# JOINT TRANSNATIONAL CALL FOR PROPOSALS (2017) FOR

"EUROPEAN INNOVATIVE RESEARCH & TECHNOLOGICAL DEVELOPMENT PROJECTS IN NANOMEDICINE"

## PRELIMINARY ANNOUNCEMENT

EuroNanoMed (ENM) is an ERA-NET on Nanomedicine established since 2008 as a platform for funding agencies and ministries to coordinate research programmes with the goal of creating and funding collaborative research projects that can convert research in nanotechnology into practical gains in medicine. Through 7 successful Joint Transnational Calls launched from 2009 to 2016, EuroNanoMed has allocated about 55 Million euros to fund 60 transnational projects in nanomedicine.

Under the umbrella of EuroNanoMed III, the **8th Joint Transnational Call** will be launched for funding multilateral innovative research projects on nanomedicine together with the European Commission under the ERA-NET Cofund mechanism:

This call is likely to open on: 14<sup>th</sup> November 2016

- Submission deadline for pre-proposals: 16<sup>th</sup> January 2017

- Submission deadline of full proposals: **9**<sup>th</sup> **June 2017** 

- Available budget for this Call: 14 Mio€ (aprox.)

### AIMS OF THE CALL

EuroNanoMed aims (i) to support translational research projects that combine innovative approaches in the field of nanomedicine and; (ii) to encourage and enable transnational collaboration between public and private research groups from academia, clinical/public health research or research teams from industrial enterprises (all size). The participation of Medical Doctors and SMEs will be strongly encouraged.





#### TOPICS OF THE CALL

Project proposals will address multidisciplinary and translational research. Project proposals will need to cover at least one of the following areas that are equal in relevance for this call:

- a) Regenerative medicine
- b) Diagnostics
- c) Targeted delivery systems

The projects should fall within Technology Readiness Levels (TRL)<sup>1</sup> 3-6, although for being realistic and coherent with the characteristics of the call, projects should propose advancements for a maximum of two TRL levels during their lifetime.

#### GENERAL CONDITIONS FOR APPLICATION

A consortium applying to this call will be required to include research group(s) from at least 2 of the 3 following categories, if eligible according to relevant national/regional funding organisations' regulations for research funding<sup>2</sup>:

- **Academia** (research teams working in universities, other higher education institutions or research institutes);
- Clinical/public health sector (research teams working in hospitals/public health and/or other health care settings and health organisations). Participation of Medical Doctors is encouraged;
- **Enterprise** (all sizes of private companies). Participation of small and medium-size enterprises (SMEs) will be encouraged.

<sup>2</sup>Whilst applications will be submitted jointly by groups from several countries, individual groups will be funded by the individual EuroNanoMed III funding organisation respective of the country/region from which applicants have applied. The applications are therefore subjected to eligibility criteria of individual funding organisations. Applicants are strongly advised to contact their national representatives as soon as possible in order to confirm with their eligibility.

Only transnational projects will be funded. Each consortium submitting a proposal will need to involve a minimum of 3 eligible and a maximum of 5 eligible partners from at least 3 different countries participating to the call (see list below) though no more than 2 eligible partners from the same country participating in the call will be accepted in one consortium.

<sup>-</sup>

<sup>&</sup>lt;sup>1</sup> Horizon 2020 scale for TRL: <a href="https://ec.europa.eu/research/participants/data/.../h2020-wp1415-annex-g-trl\_en.pdf">https://ec.europa.eu/research/participants/data/.../h2020-wp1415-annex-g-trl\_en.pdf</a>





Research groups not eligible to be funded (e.g. from non-funding countries or not fundable according to national/regional regulations of the participating funding countries) may participate in transnational projects if they are able to secure their own funding. However, no more than one research group with own funding can be included in a consortium <u>and the coordinator</u> must be eligible to be funded by EuroNanoMed III participating countries/regions.

The maximum number of partners will possibly be increased from 5 to 7 (including eligible for funding and non-eligible for funding research groups) if partners from these participating countries, which are either new in the EuroNanoMed consortium or their community has been under-represented in past EuroNanoMed calls: Belgium, Estonia, Ireland, Latvia, Lithuania, Romania, Slovakia, Taiwan, and Turkey (see table below).

Number of partners requesting funding (eligible partners)	3	4	5	6 (only with at least one underrepresented)	7 (only with at least 2 underrepresented)
Possible number of additional partners with own funding	1	1	1	1	0

#### PARTICIPATING MEMBERS, ASSOCIATED COUNTRIES AND REGIONS

Belgium / French speaking community, Canada (Quebec), Estonia, France, Germany, Greece, Ireland, Israel, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Romania, Slovakia, Spain, Taiwan and Turkey (contact list is provided in Annex).

#### **Please Note:**

The information provided in this pre-announcement is indicative and may be subject to changes and is not legally binding to funding organisations. Additional funding organisations might join the call before the official publication.

Interested applicants are encouraged to initiate scientific contacts with potential project consortium partners for applications.

Final call information is expected to be published on the EuroNanoMed website by **mid-November 2016.** 

For more info please visit: http://www.euronanomed.net/

## CONTACT DETAILS OF PARTICIPATING MEMBERS

Country	Funding Organisation	Contact point	Email
Belgium	FNS-FNRS	Arnaud Goolaerts	arnaud.goolaerts@frs-fnrs.be
Canada (Québec)	FRQS	Karine Genest Anne-Cécile Desfaits	Karine.genest@frq.gouv.qc.ca Annececile.desfaits@frq.gouv.qc.ca
Estonia	ETAg	Aare Ignat	Aare.ignat@etag.ee
France	ANR	Amélie Vergne	ENMCalls@anr.fr
Germany	VDI Technologiezentrum GmbH	Alexandra Brennscheidt	brennscheidt@vdi.de
Greece	GSRT	Paraskevi Afentaki	pafe@gsrt.gr
Ireland	SFI	Louise Rocks	louise.rocks@sfi.ie
Israel	CSO-MOH	Irit Allon	Irit.allon@moh.gov.il
Italy	IMH	Gaetano Guglielmi	g.guglielmi@sanita.it research.eu.dgric@sanita.it
Italy	MIUR	Aldo Covello Andrea Pompozzi	aldo.covello@miur.it andrea.pompozzi@miur.it
Latvia	VIAA	Linda Vecbiskena	Linda.Vecbiskena@viaa.gov.lv
Lithuania	RCL	Laura Kostelnickienė	laura.kostelnickiene@lmt.lt
The Netherlands	STW	Melvin Kasanrokijat	m.kasanrokijat@stw.nl
Norway	RCN	Cecilie A. Mathiesen	cam@rcn.no
Poland	NCBR	Aleksandra Mościcka- Studzińska	aleksandra.moscicka@ncbr.gov.pl
Romania	UEFISCDI	Mihaela Manole	mihaela.manole@uefiscdi.ro
Romania	ANCSI	loana Ispas	ioana.ispas@ancs.ro
Slovakia	SAS	Katarina BIBOVA Jan BARANCIK	bibova@up.upsav.sk barancik@up.upsav.sk
Spain	MINECO	Carles Cané Leonor Gómez	era-nano@mineco.es
Spain	ISCIII	María Druet	mdruet@isciii.es
Spain	CDTI	Juan Luis Romera	juanluis.romera@cdti.es
Taiwan	MOST	Louis Chen	ymchen@most.gov.tw
Turkey	TUBITAK	Mahmut OZER	mahmut.ozer@tubitak.gov.tr